0074-1055-01 — Telisotuzumab Vedotin-tllv 100 Mg/5 Ml Reconstituted IV Soln
Cite this view
HANK Price Transparency. (n.d.). TELISOTUZUMAB VEDOTIN-TLLV 100 MG/5 ML RECONSTITUTED IV SOLN (NDC 0074-1055-01) negotiated rates. PPMan price-transparency data, derived from CMS-required hospital MRFs. Retrieved , from http://ppman.hank.ai/transparency/code/0074-1055-01?code_type=NDC
“TELISOTUZUMAB VEDOTIN-TLLV 100 MG/5 ML RECONSTITUTED IV SOLN (NDC 0074-1055-01) negotiated rates.” HANK Price Transparency, http://ppman.hank.ai/transparency/code/0074-1055-01?code_type=NDC. Accessed .
“TELISOTUZUMAB VEDOTIN-TLLV 100 MG/5 ML RECONSTITUTED IV SOLN (NDC 0074-1055-01) negotiated rates,” HANK Price Transparency, accessed , http://ppman.hank.ai/transparency/code/0074-1055-01?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital machine-readable files (45 CFR 180). See methodology.
Usually $27,960–$27,960 (25th–75th percentile) across 1 hospital · 1 payer.
“Negotiated” is the hospital’s negotiated facility rate for this NDC 0074-1055-01 — the consumer-grade median across the country. It covers the facility charge only; the surgeon’s and anesthesiologist’s fees are billed separately.
Per-month price trends are temporarily unavailable while we rebuild them on quality-filtered rates. The medians, percentiles, and per-hospital rates on this page are the quality-filtered figures.
Hospital rates (per row)
Showing consumer-grade rates only. Flagged / outlier filings (excluded from the medians above) are hidden — tick “Show flagged / outlier rates” to include them.
| Hospital | Payer | Plan | Negotiated rate | Gross | Cash | Observed | Source |
|---|---|---|---|---|---|---|---|
| GREATER BALTIMORE MEDICAL CENTER BothFacility | ALL PAYERS | ALL PLANS | $27,960.00 | $27,960.00 | $27,400.80 | 2026-07-01 | MRF ↗ |